FDA Approves Expanded Indication for Actemra in RA

October 12th, 2012

The expanded indication in rheumatoid arthritis further supports the safety and efficacy profile of Actemra.

On October 12, the FDA expanded the use of Actemra® (tocilizumab) so it can now be used to treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

News in brief

• Earlier treatment with a biologic medicine may prevent irreversible joint damage in RA patients who experience rapid disease progression.
• Actemra, a biologic, can be used both alone as a single-agent therapy and in combination with methotrexate (MTX) or other DMARDs.

About Rheumatoid Arthritis

RA is a chronic inflammatory form of arthritis and an autoimmune disease. RA can affect many tissues and organs in the body, but it primarily attacks the joints, sometimes leading to permanent disability.

Learn more